China https://www.bioworld.com/rss en-us Mabwell announces Chinese clinical trial clearance for SST-001 http://www.bioworld.com/articles/730374 Wed, 15 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730374-mabwell-announces-chinese-clinical-trial-clearance-for-sst-001 Radiopharmaceutical illustration New China biotech Syneron chases macrocycle frontier http://www.bioworld.com/articles/730420 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730420-new-china-biotech-syneron-chases-macrocycle-frontier Multicolor peptide illustration New China biotech Syneron chases macrocycle frontier http://www.bioworld.com/articles/730152 Wed, 08 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730152-new-china-biotech-syneron-chases-macrocycle-frontier Multicolor peptide illustration Fosun gains clinical trial approval in China for FXB-0871 http://www.bioworld.com/articles/730093 Thu, 02 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730093-fosun-gains-clinical-trial-approval-in-china-for-fxb-0871 3D illustration of tumor Trade secret theft results in loss of US citizenship http://www.bioworld.com/articles/729983 Wed, 01 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/729983-trade-secret-theft-results-in-loss-of-us-citizenship Lilly taps Insilico AI in $2.75B deal to expand pipeline options http://www.bioworld.com/articles/730091 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/730091-lilly-taps-insilico-ai-in-275b-deal-to-expand-pipeline-options Pill in immersive interface Innovent’s IBI-302 meets phase III endpoints in neovascular AMD http://www.bioworld.com/articles/730089 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/730089-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd Woman taking Amsler grid eye exam China-developed triple incretin enters global diabetes race http://www.bioworld.com/articles/730088 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/730088-china-developed-triple-incretin-enters-global-diabetes-race Illustration of glucose molecules in a bloodstream Simcere’s rademikibart meets phase III endpoints in atopic dermatitis http://www.bioworld.com/articles/729969 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729969-simceres-rademikibart-meets-phase-iii-endpoints-in-atopic-dermatitis Monoclonal antibody illustration Braveheart finds phase II positive for cardiac myosin inhibitor http://www.bioworld.com/articles/729968 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729968-braveheart-finds-phase-ii-positive-for-cardiac-myosin-inhibitor 3D illustration of heart cross section Lilly taps Insilico AI in $2.75B deal to expand pipeline options http://www.bioworld.com/articles/729949 Mon, 30 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729949-lilly-taps-insilico-ai-in-275b-deal-to-expand-pipeline-options Pill in immersive interface China-developed triple incretin enters global diabetes race http://www.bioworld.com/articles/729901 Thu, 26 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729901-china-developed-triple-incretin-enters-global-diabetes-race Illustration of glucose molecules in a bloodstream Innovent’s IBI-302 meets phase III endpoints in neovascular AMD http://www.bioworld.com/articles/729841 Wed, 25 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729841-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd Woman taking Amsler grid eye exam Excalipoint closes $68.7M seed round for cancer T-cell engagers http://www.bioworld.com/articles/729898 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729898-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers Blue-gray dollar sign Simcere’s PD-L1/IL-15 bispecific sees early edge in bladder cancer http://www.bioworld.com/articles/729895 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729895-simceres-pd-l1-il-15-bispecific-sees-early-edge-in-bladder-cancer Bladder cancer illustration Kintor’s KX-826 meets phase III endpoints in alopecia http://www.bioworld.com/articles/729893 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729893-kintors-kx-826-meets-phase-iii-endpoints-in-alopecia Alopecia - hair loss China’s pharma rise rattles US policymakers http://www.bioworld.com/articles/729830 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729830-chinas-pharma-rise-rattles-us-policymakers China and U.S. flags Gilead pens dual-purpose $2B Ouro M&A deal with Galapagos http://www.bioworld.com/articles/729829 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729829-gilead-pens-dual-purpose-2b-ouro-m-and-a-deal-with-galapagos Hands holding gears Kelun-Biotech’s SKB-103 cleared to enter clinic in China http://www.bioworld.com/articles/729855 Tue, 24 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729855-kelun-biotechs-skb-103-cleared-to-enter-clinic-in-china 3D illustration demonstrating antibody-drug conjugate. Kintor’s KX-826 meets phase III endpoints in alopecia http://www.bioworld.com/articles/729749 Thu, 19 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729749-kintors-kx-826-meets-phase-iii-endpoints-in-alopecia Alopecia - hair loss Excalipoint closes $68.7M seed round for cancer T-cell engagers http://www.bioworld.com/articles/729788 Thu, 19 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729788-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers Blue-gray dollar sign Simcere’s PD-L1/IL-15 bispecific sees early edge in bladder cancer http://www.bioworld.com/articles/729564 Wed, 18 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729564-simceres-pd-l1-il-15-bispecific-sees-early-edge-in-bladder-cancer Bladder cancer illustration Excalipoint closes $68.7M seed round for cancer T-cell engagers http://www.bioworld.com/articles/729560 Wed, 18 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729560-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers Blue-gray dollar sign China’s Qyuns moves IL-17 biologic toward first approval http://www.bioworld.com/articles/729710 Tue, 17 Mar 2026 11:00:00 -0400 https://www.bioworld.com/articles/729710-chinas-qyuns-moves-il-17-biologic-toward-first-approval Illustration of inflamed spine R1’s $77.5M series A to fund CKD trial of oral phosphate inhibitor http://www.bioworld.com/articles/729551 Tue, 17 Mar 2026 08:00:00 -0400 https://www.bioworld.com/articles/729551-r1s-775m-series-a-to-fund-ckd-trial-of-oral-phosphate-inhibitor Kidneys CF Pharmtech’s ICF-001 cleared for clinic in China http://www.bioworld.com/articles/729648 Mon, 16 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729648-cf-pharmtechs-icf-001-cleared-for-clinic-in-china Internal organs: lungs, heart, stomach, diaphragm China NMPA clears IND for Akeso’s trispecific antibody http://www.bioworld.com/articles/729646 Mon, 16 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729646-china-nmpa-clears-ind-for-akesos-trispecific-antibody Concept art for targeting cancer China’s Qyuns moves IL-17 biologic toward first approval http://www.bioworld.com/articles/729467 Wed, 11 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729467-chinas-qyuns-moves-il-17-biologic-toward-first-approval Illustration of inflamed spine China approves first noninvasive therapy for cervical precancer http://www.bioworld.com/articles/729585 Tue, 10 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729585-china-approves-first-noninvasive-therapy-for-cervical-precancer Fallopian tubes, ovaries and uterus Sanofi licenses Sino Biopharm’s JAK/ROCK drug for $1.4B http://www.bioworld.com/articles/729584 Tue, 10 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729584-sanofi-licenses-sino-biopharms-jak-rock-drug-for-14b Gold dollar sign inside gold cog